Clareo Health | Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.
Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Thessaly
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Crohn's disease: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month.
Ulcerative colitis: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month.
Hypertension: Patients with systolic blood pressure of 130-139 mmHg or diastolic blood pressure of 80-89 mmHg, who maintain blood pressure within these ranges through lifestyle modifications, without active symptoms (e.g., headaches, dizziness), and not receiving antihypertensive medication.
Anemia: Patients with hemoglobin \<12 g/dL, serum iron \<40 μg/dL, and ferritin \<15 ng/mL for women, and hemoglobin \<13 g/dL, serum iron \<40 μg/dL, and ferritin \<30 ng/mL for men. Absence of severe clinical consequences. Presence of fatigue, weakness, or dizziness, which is usually manageable.
Multiple sclerosis: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month.
You may not be if
Pregnancy or breastfeeding
Current use of antibiotics or antibiotic use within the past month
Current use of other probiotic, prebiotic, or synbiotic supplements
Current use of iron and/or zinc supplements
Change in the type of therapeutic regimen (pharmacotherapy) within the past three months
Change in the dosage of the therapeutic regimen (pharmacotherapy) within the past month
Renal or hepatic disease
Inability to provide informed consent (including individuals \<18 years of age)
